Colgate-Palmolive Company
CLFinancial Snapshot
ticker: CL step: 04 generated: 2026-05-13 source: quick-research
Colgate-Palmolive Company (CL) — Financial Snapshot
Income Statement Summary
| Metric | FY2022 | FY2023 | FY2024 | YoY |
|---|---|---|---|---|
| Revenue | $17.97B | $19.46B | $20.10B | +3.3% |
| Gross Margin | ~56% | ~58% | 60.5% | |
| Operating Margin | ~18% | ~20% | 21.8% | |
| Net Income | ~$1.8B | ~$2.1B | ~$2.8B | +33% |
| EPS (diluted) | ~$2.12 | ~$2.49 | $3.51 (GAAP) / $3.60 (Base) | +40%/+11% |
FY2024 GAAP EPS +27% reflects both operating improvement and tax/restructuring items. Base Business EPS +11% better reflects underlying earnings power.
Cash Flow & Balance Sheet (FY2024)
| Metric | Value |
|---|---|
| Operating Cash Flow | ~$4.1B |
| Free Cash Flow | ~$3.55B |
| Capital Expenditures | ~$550M |
| Cash & Equivalents | ~$1.1B |
| Total Debt | ~$7.3B (net debt ~$6.2B) |
FCF of $3.55B represents ~17.7% FCF margin — best-in-class for consumer staples. Company returned $3.4B to shareholders via dividends + buybacks in FY2024.
Key Ratios (approximate)
- P/E: ~21x | EV/EBITDA: ~16x | Dividend Yield: ~2.5%
- Revenue Growth (FY2024): +3.3% (organic +7.4%) | FCF Margin: ~17.7%
- Gross Margin: 60.5% (six-year high driven by pricing + cost discipline)
Growth Profile
Colgate has delivered six consecutive years of 3%+ organic sales growth — an extraordinary streak for a $20B consumer staples company. FY2024 organic growth of 7.4% was driven by a mix of pricing and modest volume recovery. FY2025 organic sales growth was positive, with FY2025 revenue at ~$20.4B (+1.4% reported, but tariff headwinds forced a guidance cut). Hill's Pet Nutrition has been the standout growth engine, with revenue nearly doubling in five years on premium veterinary nutrition trends.
Forward Estimates
- FY2025 Revenue: ~$20.4B (actual); tariff headwind of $200M reduced EPS trajectory
- FY2026 Revenue guidance: +2% to +6% net sales growth; Low-to-mid single-digit Base Business EPS growth
- Management targets gross margin expansion in 2026 and double-digit EPS growth on 2030 plan horizon
- $5B share repurchase authorization announced — supportive of per-share earnings growth
Deeper Financial Analysis
The fundamental tier adds 9 additional research dimensions for $CL.